October 21, 2016 8:39 AM ET


Company Overview of Napo Pharmaceuticals, Inc.

Company Overview

Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace. Its MercuryWise product focuses on addressing personal risk from exposure to routine levels of mercury. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc. The company was founded in 2001 and is based in San Francisco, California.

185 Berry Street

Suite 1300

San Francisco, CA 94107

United States

Founded in 2001

21 Employees





Key Executives for Napo Pharmaceuticals, Inc.

Founder, Chief Executive Officer and Executive Director
Age: 57
President and Chief Scientific Officer
Age: 53
Chief Financial Officer
Age: 58
President of Napo India Private Limited
Age: 72
Senior Vice President of Global Access and Alliances
Compensation as of Fiscal Year 2016.

Napo Pharmaceuticals, Inc. Key Developments

Napo Pharmaceuticals, Inc. Launches and General Availability of Mytesi (crofelemer)

Napo Pharmaceuticals, Inc. announced the launch and general availability of Mytesi (crofelemer), the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV+ patients. Previously marketed as Fulyzaq, the product launch under the Mytesi brand importantly includes the unveiling of the Mytesi Copay Savings Program and NapoCares™ Patient Assistance Program to provide people living with HIV/AIDS with broad, affordable access to the drug.

Salix Pharmaceuticals, Inc. and Napo Pharmaceuticals, Inc. Settles Litigation

Salix Pharmaceuticals, Inc. and Napo Pharmaceuticals, Inc. announced the settlement of Napo’s litigation with Salix. As part of the settlement, the collaboration agreement between Salix and Napo dated December 9, 2008 has been terminated. Accordingly, Napo has regained the rights for Fulyzaq® (crofelemer) which has been approved by the FDA for the systematic relief of non-infectious diarrhea in adults with HIV/AIDs on antiretroviral therapy as well as the rights for the development and commercialization of: Crofelemer for diarrhea predominant irritable bowel syndrome (CRO-IBS), Phase 2, worldwide; Crofelemer for acute infectious diarrhea, including cholera (CRO-ID), Phase 2, Western Territories including the US, most EU and Japan; Crofelemer for pediatric diarrhea (CRO-PED), Phase 1, Western Territories including the US, most EU and Japan. Napo will assume all commercial and regulatory responsibility for Fulyzaq® within thirty-(30) days and is developing plans for the further development of crofelemer for other potential indications. As part of the Settlement, Napo will receive all finished product inventory and inventory used in the production of crofelemer API.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

October 6, 2016
Jaguar Animal Health, Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Napo Pharmaceuticals, Inc., please visit www.napopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.